Loading…
← CockpitCompetitor Analysis › 600521.SS Zhejiang Huahai Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Huahai Pharmaceutical Co., Ltd. Class A600521.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese maker of active pharmaceutical ingredients and generic formulations, a major API exporter to the US and European generics markets.

Momentum leader 85
Mkt cap
$3.61B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$61.9M
20-day average traded
Fwd P/E
20.1×
forward earnings
ROIC−WACC
+2.0 pp
WACC 6.6%
Hurdle
+1 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥16.48
1D-0.8%
1W-4.3%
1M-1.6%
3M-8.4%
6M-0.2%
YTD-2.9%
1Y-10.5%
ATR %3.2%
52w lowhigh13.9% off high

What Zhejiang Huahai Pharmaceutical does

Chinese maker of active pharmaceutical ingredients and generic formulations, a major API exporter to the US and European generics markets.

Sells active ingredients to generic-drug makers worldwide, including the US and Europe, and finished generics under its own filings, so approvals by the FDA and EU regulators decide what it can ship. A 2018 impurity found in its valsartan ingredient led to recalls and regulatory action, and quality compliance has weighed on the business since.

Products and services

  • Active pharmaceutical ingredients (APIs)
  • Generic formulations (incl. US ANDA filings)

Customers

  • Global generic-drug manufacturers
  • Hospitals/pharmacies (own formulations)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • API manufacturing + generic…

What could go right

  • Generic-drug demand growth globally

What could go wrong

  • Regulatory/quality-compliance risk (past valsartan recall)
  • API price competition

Moat: narrow (regulatory licence, scale). FDA/EU-approved API facilities and a large ANDA portfolio, though past quality lapses have hurt trust.

Headquarters: Linhai, Zhejiang, China · Employees: 8,797

Named competitors

Zhejiang Huahai Pharmaceutical at a glance

Size Zhejiang Huahai Pharmaceutical (600521.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.61B, the 668th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.48 on 18 Nov 2026.

Performance Over six months the shares fell 0.2%, against +8.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 10.3% over the last twelve months (peer median +11.9%); the operating margin is 12.2% (peer median 16.8%).

Valuation It trades at 20.1× forward earnings against a peer median of 20.7× (7th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.0 points above its cost of capital (6.6% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 111600521.SS 102
Six months, rebased to 100: Zhejiang Huahai Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Huahai Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥9.60BCN¥8.54BCN¥9.49BCN¥8.26BCN¥8.23B
Revenue growth—-10%+15%0%—
Gross profitCN¥6.13BCN¥4.70BCN¥5.50BCN¥4.68BCN¥4.88B
EBITDAn/aCN¥1.59BCN¥2.49BCN¥2.08BCN¥2.20B
Net incomeCN¥946MCN¥266MCN¥1.12BCN¥830MCN¥1.17B
Free cash flowCN¥249M-CN¥734MCN¥320MCN¥630M-CN¥1.07B
Capital expenditureCN¥1.86BCN¥1.97BCN¥1.85BCN¥1.59BCN¥2.32B
Total debtCN¥8.94BCN¥8.66BCN¥8.07BCN¥7.45BCN¥7.42B

Quarterly statements and history in the cockpit →

Zhejiang Huahai Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%3320OGNSLSWOCKPHARMASFZNXENEACUTAAS1877ARQT1513002262ROVI600329AMLXVRDN688336PPLPHARMA600521.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Huahai Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×50×100×150×3320OGNSFZNACUTAASARQT1513600329688336PPLPHARMA600521.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Huahai Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%3320OGNWOCKPHARMAARQTTARS600329688336600521.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Huahai Pharmaceutical is the large dot.

Zhejiang Huahai Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600521.SS vs 000739.SZ vs 603456.SS vs 600267.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%
Apeloa Pharmaceutical 000739.SZ$3.37B+17%-16%10%22.9×4.7%
Zhejiang Jiuzhou Pharmaceutical 603456.SS$2.03B+19%-1%14%16.9×1.7%
Zhejiang Hisun Pharmaceutical 600267.SS$2.19B+14%-7%15%15.0×-9.7%
Zhejiang Xianju Pharmaceutical 002332.SZ$1.28B-1%+8%11%17.7×-0.4%
Zhejiang Medicine 600216.SS$1.51B-26%-6%7%11.5×-7.8%
Aurobindo Pharma AUROPHARMA.NS$11.0B+19%+14%15%22.3×21.1%
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%32.0×30.7%

How Zhejiang Huahai Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Huahai Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600521.SSPeer medianRank in peer set
1-month return-1.6%+4.5%9th lowest of 21
6-month return-0.2%+8.1%9th lowest of 20
Distance from 52-week high-13.9%-23.4%6th highest of 21
Revenue growth (TTM)+10.3%+11.9%10th highest of 19
Operating margin12.2%16.8%7th lowest of 17
Forward P/E20.1×20.7×7th cheapest of 13
Growth the price implies (Req g, 7 yrs)6.4%0.9%5th most demanding of 12
Growth delivered (Del g)+5.9%+10.6%5th lowest of 12
Hurdle (Req g minus delivered)+0.5 pp-12.7 pp3rd most demanding of 12
ROIC minus cost of capital+2.0 pp+5.6 pp7th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a

Questions

Who are Zhejiang Huahai Pharmaceutical's main competitors?
Named competitors: Apeloa Pharmaceutical (000739.SZ), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Zhejiang Hisun Pharmaceutical (600267.SS), Zhejiang Xianju Pharmaceutical (002332.SZ), Zhejiang Medicine (600216.SS), Aurobindo Pharma (AUROPHARMA.NS). The cockpit's measured peer set (industry) also includes China Resources Pharmaceutical (3320.HK), Organon & (OGN), SELLAS Life Sciences (SLS), Wockhardt (WOCKPHARMA.NS), Parabilis Medicines (PBLS), Siegfried (SFZN.SW).
Is Zhejiang Huahai Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 20.1× against a peer median of 20.7×, 7th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhejiang Huahai Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -0.2% against +8.1% for the median peer; over one year -10.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.